Skip to Main Content

Author Details

Prapti Patel
The University of Texas Southwestern Medical Center
2009
40
12
PMIDPaper TitleJournal TitlePublished Year
37871309A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Blood Adv2024
36222845Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.Cancer Discov2023
37587783Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self-administered questionnaire to an initial screening platform.Eur J Haematol2023
37576365Anti-Spike Antibody Responses in Allogeneic Stem Cell Transplant Recipients to Two Doses of COVID-19 mRNA Vaccination: A Retrospective, Single-Center Analysis.J Adv Pract Oncol2023
37326395SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.Acta Med Acad2023
37052347Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.Leuk Lymphoma2023
37078412Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.Cancer2023
36517346Image-guidance triggered adaptive radiation therapy in head and neck squamous cell carcinoma: single-institution experience and implications for clinical practice.J Med Imaging Radiat Sci2023
36842566Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.Transpl Immunol2023
36315007Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.Blood Adv2023
34775145Volumetric Modulated Arc Therapy Enabled Total Body Irradiation (VMAT-TBI): Six-year Clinical Experience and Treatment Outcomes.Transplant Cell Ther2022
35096610<i>Post-hoc</i> Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.Front Oncol2022
35133215The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis.Leuk Lymphoma2022
34454850Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Clin Lymphoma Myeloma Leuk2022
34482403Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.Blood2022
33119479Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.J Clin Oncol2021
33781572Corrigendum to "The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement" [Leukemia Res. 100 (2021) 106480].Leuk Res2021
34439266A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.Cancers (Basel)2021
34771451Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.Cancers (Basel)2021
33285315The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.Leuk Res2021
33024987Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.Blood2021
31468521A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.Br J Haematol2020
33106665Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.Nat Med2020
32998961A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.Clin Cancer Res2020
32880627Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.Am J Clin Pathol2020
32453640Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.J Clin Oncol2020
30760466Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.Blood Adv2019
35100680Next-Generation Sequencing Directs Therapy and Delineates a Clonal Relationship in Mast Cell Sarcoma and Acute Myeloid Leukemia.JCO Precis Oncol2019
31501157Persistence of skewed X-chromosome inactivation in pre-B acute lymphoblastic leukemia of a female ATRX mutation carrier.Blood Adv2019
29722657Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy.Int J Radiat Oncol Biol Phys2018
30327177What's in a name? The heterogeneous clinical spectrum and prognostic factors in a cohort of adults with hemophagocytic lymphohistiocytosis.Transfus Apher Sci2018
28512017A case of autoimmune severe acquired von Willebrand syndrome (type 3-like).Transfus Apher Sci2017
28377936Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation.ACG Case Rep J2017
24600172Radiation dose verification using real tissue phantom in modern radiotherapy techniques.J Med Phys2014
25190995Impact of repeat computerized tomography replans in the radiation therapy of head and neck cancers.J Med Phys2014
25313743A study on the necessity of kV-CBCT imaging compared to kV-orthogonal portal imaging based on setup errors: considering other socioeconomical factors.J Cancer Res Ther2014
22520262Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors.Cancer Treat Rev2013
21301320Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.Anticancer Drugs2011
21139894Metastatic rectal cancer to the breast.Rare Tumors2009
23133191Current evidence-based opinions in the management of adenocarcionoma of the rectum.Indian J Surg2009
  • 1 - 40 of 40

Recommended Authors

Felipe Batalini
Mayo Clinic Arizona
Career Start Year 2015
Number of shared co-authors 1
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Shalin Kothari
Yale University
Career Start Year 2013
Number of shared co-authors 0
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 20
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 2
Milos D Miljkovic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2009
Number of shared co-authors 3
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 5
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 2
Aarthi Shenoy
MedStar Washington Hospital Center
Career Start Year 2006
Number of shared co-authors 1
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 16
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 2
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 0
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 5
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 5
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 10
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 0
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 3
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 4
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 16
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 5
Nam Bui
Stanford University
Career Start Year 1996
Number of shared co-authors 0
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 12
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 5
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 0
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 14
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 5
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 8
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 22
Mark Lawler
Queens University Belfast Belfast
Career Start Year 1988
Number of shared co-authors 1

Collaborators

Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 15
Tara L Lin
University of Kansas Medical Center
Co-authored papers 7
Uma Borate
The Ohio State University
Co-authored papers 6
Brian J Druker
Oregon Health & Science University
Co-authored papers 5
John T Schiller
David Geffen School of Medicine at university of california los angeles
Co-authored papers 5
Christopher R Cogle
College of Medicine, University of Florida
Co-authored papers 4
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Co-authored papers 3
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 3
Elie Traer
Oregon Health & Science University
Co-authored papers 3
Neil B Desai
University of Texas Southwestern Medical Center
Co-authored papers 2
Courtney D DiNardo
UT MD Anderson Cancer Center
Co-authored papers 2
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 2
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 2
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 2
Nicola Long
Oregon Health and Science University
Co-authored papers 1
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Jose Solis-Ruiz
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Stefania Pittaluga
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Al B Benson
Northwestern University Feinberg School of Medicine
Co-authored papers 1
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Allison M Bock
Mayo Clinic
Co-authored papers 1
Ronan Swords
Oregon Health and Science University
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Srinidhi Radhakrishnan
University of Texas Southwestern Medical Center
Co-authored papers 1
Ujwal Shinde
Oregon Health & Science University
Co-authored papers 1
John M Kirkwood
UPMC Hillman Cancer Center
Co-authored papers 1
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Bruno C Medeiros
AbbVie Inc.
Co-authored papers 1
Emmanuel Raffoux
Universite Paris Diderot
Co-authored papers 1
Release 1.2